Payments to Acquire Property, Plant, and Equipment of Revance Therapeutics, Inc. from 31 Dec 2012 to 31 Mar 2024

Taxonomy & unit
us-gaap: USD
Description
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
Summary
Revance Therapeutics, Inc. quarterly and annual Payments to Acquire Property, Plant, and Equipment in USD history and change rate from 31 Dec 2012 to 31 Mar 2024.
  • Revance Therapeutics, Inc. Payments to Acquire Property, Plant, and Equipment for the quarter ending 31 Mar 2024 was $1,712,000, a 97% increase year-over-year.
  • Revance Therapeutics, Inc. annual Payments to Acquire Property, Plant, and Equipment for 2023 was $6,886,000, a 115% increase from 2022.
  • Revance Therapeutics, Inc. annual Payments to Acquire Property, Plant, and Equipment for 2022 was $3,210,000, a 69% decline from 2021.
  • Revance Therapeutics, Inc. annual Payments to Acquire Property, Plant, and Equipment for 2021 was $10,375,000, a 153% increase from 2020.
Source SEC data
View on sec.gov
Payments to Acquire Property, Plant, and Equipment, Quarterly (USD)
Payments to Acquire Property, Plant, and Equipment, YoY Quarterly Change (%)
Payments to Acquire Property, Plant, and Equipment, Annual (USD)
Payments to Acquire Property, Plant, and Equipment, YoY Annual Change (%)

Revance Therapeutics, Inc. Quarterly Payments to Acquire Property, Plant, and Equipment (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q1 2024 $1,712,000 +$842,000 +97% 01 Jan 2024 31 Mar 2024 10-Q 09 May 2024 2024 Q1
Q1 2023 $870,000 -$586,000 -40% 01 Jan 2023 31 Mar 2023 10-Q 09 May 2024 2024 Q1
Q1 2022 $1,456,000 -$2,580,000 -64% 01 Jan 2022 31 Mar 2022 10-Q 09 May 2023 2023 Q1
Q1 2021 $4,036,000 +$3,497,000 +649% 01 Jan 2021 31 Mar 2021 10-Q 10 May 2022 2022 Q1
Q1 2020 $539,000 -$545,000 -50% 01 Jan 2020 31 Mar 2020 10-Q 10 May 2021 2021 Q1
Q1 2019 $1,084,000 +$16,000 +1.5% 01 Jan 2019 31 Mar 2019 10-Q 07 May 2020 2020 Q1
Q1 2018 $1,068,000 +$772,000 +261% 01 Jan 2018 31 Mar 2018 10-Q 09 May 2019 2019 Q1
Q1 2017 $296,000 -$394,000 -57% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q1 2016 $690,000 -$1,111,000 -62% 01 Jan 2016 31 Mar 2016 10-Q 09 May 2017 2017 Q1
Q1 2015 $1,801,000 +$816,000 +83% 01 Jan 2015 31 Mar 2015 10-Q 10 May 2016 2016 Q1
Q1 2014 $985,000 +$660,000 +203% 01 Jan 2014 31 Mar 2014 10-Q 14 May 2015 2015 Q1
Q1 2013 $325,000 01 Jan 2013 31 Mar 2013 10-Q 14 May 2014 2014 Q1

Revance Therapeutics, Inc. Annual Payments to Acquire Property, Plant, and Equipment (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2023 $6,886,000 +$3,676,000 +115% 01 Jan 2023 31 Dec 2023 10-K 28 Feb 2024 2023 FY
2022 $3,210,000 -$7,165,000 -69% 01 Jan 2022 31 Dec 2022 10-K 28 Feb 2024 2023 FY
2021 $10,375,000 +$6,277,000 +153% 01 Jan 2021 31 Dec 2021 10-K 28 Feb 2024 2023 FY
2020 $4,098,000 +$868,000 +27% 01 Jan 2020 31 Dec 2020 10-K 28 Feb 2023 2022 FY
2019 $3,230,000 -$3,761,000 -54% 01 Jan 2019 31 Dec 2019 10-K 28 Feb 2022 2021 FY
2018 $6,991,000 +$4,466,000 +177% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $2,525,000 +$855,000 +51% 01 Jan 2017 31 Dec 2017 10-K 26 Feb 2020 2019 FY
2016 $1,670,000 -$1,658,000 -50% 01 Jan 2016 31 Dec 2016 10-K 28 Feb 2019 2018 FY
2015 $3,328,000 -$3,647,000 -52% 01 Jan 2015 31 Dec 2015 10-K 02 Mar 2018 2017 FY
2014 $6,975,000 +$498,000 +7.7% 01 Jan 2014 31 Dec 2014 10-K 28 Feb 2017 2016 FY
2013 $6,477,000 +$6,158,000 +1930% 01 Jan 2013 31 Dec 2013 10-K 04 Mar 2016 2015 FY
2012 $319,000 01 Jan 2012 31 Dec 2012 10-K 04 Mar 2015 2014 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.